For 2023, Boston Scientific is also targeting 50bps annual margin expansion and "strong" free cash flow. Comments made by CEO Michael Mahoney at the JPMorgan Healthcare Conference.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BSX: